Results for "GTX-102"

Ultragenyx Pharmaceutical saw its stock drop sharply after announcing that a pivotal Phase 3 trial for its experimental Angelman syndrome therapy did not meet primary endpoints. Several financial analysts downgraded the company, though some investors remain optimistic about its broader pipeline.

Optimism for Ultragenyx Pharmaceutical (RARE) is being fueled by institutional confidence in its drug candidate, GTX-102.

Ultragenyx Pharmaceutical is garnering bullish sentiment from investors in anticipation of its forthcoming GTX-102 Phase 3 trial for Angelman Syndrome, signaling confidence in its clinical development.